紫杉醇洗脱支架治疗长达190 mm股浅动脉病变:IMPERIAL长病变亚组一年结果
IMPERIAL长病变亚组是一项前瞻性单臂多中心试验,评估Eluvia药物洗脱支架治疗长度>140 mm且≤190 mm股腘动脉病变的效果。
要点
- Eluvia支架治疗长段股腘动脉病变1年主要通畅率达91.0%。
- 12个月内无死亡、靶肢体截肢或支架血栓事件。
- 免于临床驱动的靶病变血运重建率为93.9%。
核心结论
- Eluvia药物洗脱支架在长段股腘动脉闭塞性病变中展示了优异的1年通畅性和安全性。
主要发现
- 12个月时无死亡、靶肢体截肢或支架血栓发生。
- Kaplan-Meier估计的主要通畅率为91.0%(95%CI 82.5%至99.6%)。
- 12个月无主要不良事件率为93.5%,因发生3例临床驱动的靶病变血运重建。
- Kaplan-Meier估计的免于靶病变血运重建率为93.9%(95%CI 87.2%至100%)。
关键数值与推荐
- 主要通畅定义为双功超声收缩期峰值流速比≤2.4且无临床驱动的靶病变血运重建或靶病变旁路移植。
- 主要不良事件包括30天全因死亡和1年靶肢体大截肢或靶病变血运重建。
临床怎么用
- 对于股腘动脉长段病变(>140 mm且≤190 mm),可考虑使用Eluvia药物洗脱支架以获得高1年通畅率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose: To report the clinical effect of a drug-eluting stent on femoropopliteal occlusive disease in patients with long lesions. Materials and Methods: The global IMPERIAL Long Lesion substudy (ClinicalTrials.gov identifier NCT02574481) is a prospective, single-arm, multicenter trial of the Eluvia Drug-Eluting Vascular Stent for treating femoropopliteal lesions >140 mm and ≤190 mm in length. Fifty patients (mean age 68.2 years; 32 men) with long lesions (mean length 162.8±34.7 mm) were enrolled; 20 patients had diabetes. Fourteen of the lesions were severely calcified and 16 were occluded. Primary patency (duplex ultrasound peak systolic velocity ratio ≤2.4 in the absence of clinically-driven target lesion revascularization or bypass of the target lesion) and major adverse events [30-day all-cause death and 1-year target limb major amputation or target lesion revascularization (TLR)] were assessed at 12 months. Results: At 12 months, no deaths, target limb amputations, or stent thrombosis had occurred. The Kaplan-Meier estimate of primary patency was 91.0% (95% CI 82.5% to 99.6%). The MAE-free rate at 12 months was 93.5% due to 3 clinically-driven TLRs. The corresponding Kaplan-Meier estimate of freedom from TLR was 93.9% (95% CI 87.2% to 100%). Conclusion: The IMPERIAL Long Lesion substudy demonstrated excellent patency and safety through 1 year among patients with long femoropopliteal occlusive disease treated with the Eluvia stent.
引用
- Golzar J, Soga Y, Babaev A, et al. Effectiveness and Safety of a Paclitaxel-Eluting Stent for Superficial Femoral Artery Lesions up to 190 mm: One-Year Outcomes of the Single-Arm IMPERIAL Long Lesion Substudy of the Eluvia Drug-Eluting Stent. J Endovasc Ther. 2020. PMID: 31989856. doi:10.1177/1526602820901723
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。